Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on genomics‑based transplant diagnostics and related solutions. Through these filings, investors and analysts can review how CareDx reports its financial performance, governance changes, and other material events connected to its transplant‑focused business.
CareDx uses Form 8‑K to disclose current events such as quarterly financial results, preliminary annual results, leadership and board appointments, amendments to its bylaws, and information about shareholder derivative litigation settlements. For example, recent 8‑K filings describe revenue by category (testing services, product, and patient and digital solutions), changes in executive roles, adoption of a majority voting standard for director elections, and court approval milestones for a proposed settlement of shareholder litigation.
In addition to current reports, investors typically consult annual reports on Form 10‑K and quarterly reports on Form 10‑Q for more detailed discussions of CareDx’s transplant diagnostics business, segment information, and risk factors. These periodic reports complement the 8‑K disclosures by providing broader context on the company’s operations in non‑invasive molecular testing, lab products, and patient and digital solutions for transplant care.
On Stock Titan, CareDx filings are updated as they become available from EDGAR and are paired with AI‑powered summaries that highlight key points from lengthy documents. These summaries are designed to help readers quickly understand topics such as revenue composition, governance updates, compensation arrangements, and litigation‑related disclosures, while still allowing direct access to the original SEC filings for detailed review.
CareDx, Inc. (CDNA) received an updated ownership report on its common stock from investment manager Neil Gagnon and related entities. As of the reported date, Gagnon reports beneficial ownership of 3,054,946 shares of CareDx common stock, representing 5.9% of the class.
Within this total, Gagnon Securities LLC reports beneficial ownership of 2,213,827 shares, or 4.3% of the class, and Gagnon Advisors, LLC reports 532,892 shares, or 1.0%. The filing states the securities are not held for the purpose of changing or influencing control of CareDx.
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in CareDx, Inc. (CDNA). As of 12/31/2025, State Street reports beneficial ownership of 2,737,752 shares of CareDx common stock, representing 5.3% of the outstanding class.
State Street reports shared voting power over 2,606,232 shares and shared dispositive power over 2,737,752 shares, with no sole voting or dispositive power. The position is held through investment management affiliates, including SSGA Funds Management and various State Street Global Advisors entities, and is certified as being held in the ordinary course of business without the purpose of influencing control.
CareDx Chief Operating Officer Kennedy Keith reported equity compensation and related tax withholding transactions in company common stock. On February 2, 2026, Keith received 60,000 shares represented by restricted stock units at $0 per share, which will vest over three years starting April 6, 2027. Keith also acquired 14,474 shares from performance-based restricted stock units that were earned after performance goals were certified on February 2, 2026. To cover tax obligations from the PRSU vesting, 4,644 shares were withheld at a price of $20.42 per share. After these transactions, Keith directly owns 209,139 CareDx common shares.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported equity awards and a related tax withholding transaction. On February 2, 2026, she was granted 60,000 restricted stock units (RSUs), which vest one-third on April 6, 2027 and the remaining two-thirds in eight equal quarterly installments so that all RSUs vest by the third anniversary of April 6, 2027, subject to continuous employment. She also earned 11,579 shares from a performance restricted stock unit (PRSU) award initially granted on February 1, 2025, after performance criteria were certified on February 2, 2026. In connection with the PRSU vesting, 4,430 shares of common stock were withheld at $20.42 per share to satisfy tax withholding obligations, leaving her with 176,778 directly held common shares.
CareDx, Inc. Chief Financial Officer Nathan Smith reported equity compensation and related tax withholding transactions. On February 2, 2026 he was granted 33,000 restricted stock units, which will vest in stages beginning April 6, 2027 and fully vest three years after that date, subject to continued employment.
He also acquired 7,875 common shares at no cost from a performance RSU award that was originally granted on February 1, 2025 and earned after performance goals were certified on February 2, 2026. To cover tax withholding on the PRSU vesting, 3,859 shares were withheld at a price of $20.42 per share, leaving him with 79,016 directly owned shares.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported multiple equity transactions in company common stock. He was granted 33,000 restricted stock units that begin vesting on April 6, 2027 over three years, subject to continued employment, and 4,342 shares from a performance RSU award earned after performance criteria were certified on February 2, 2026. To cover tax withholding on PRSU and RSU vesting, 2,492 and 2,970 shares, respectively, were withheld by CareDx. On February 3, 2026, 4,441 shares were sold at $20.5553 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Novack directly held 125,364 shares of CareDx common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported equity compensation and related tax withholding transactions. On February 2, 2026, he was granted 162,500 restricted stock units (RSUs) at $0 per share. One-third of these RSUs will vest on April 6, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following eight quarters, so that all RSUs vest by the third anniversary of April 6, 2027, subject to continued employment.
He also acquired 37,632 shares of common stock at $0 per share, earned from a performance restricted stock unit (PRSU) award initially granted on February 1, 2025, after performance criteria were certified on February 2, 2026. To cover tax withholding on the PRSU vesting, 13,694 shares were withheld at a price of $20.42 per share. After these transactions, he directly owned 783,843 shares of CareDx common stock.
CareDx, Inc. insider Jeffrey Novack has filed a Form 144 notice to sell company stock. The filing covers a proposed sale of 4,441 shares of CareDx common stock through Morgan Stanley Smith Barney LLC on the NASDAQ market, with an aggregate market value of $90,685.22 and 51,432,639 shares of common stock outstanding.
The shares to be sold were acquired on 02/01/2026 via 2,591 restricted stock units and 1,850 performance stock units from the issuer, both settled on 02/01/2026. Over the past three months, Form 144 discloses additional 10b5-1 sales for Jeffrey Novack totaling 7,293 shares on 12/04/2025 and 2,688 shares on 11/07/2025, with gross proceeds of $139,804.74 and $41,722.87, respectively.
CareDx, Inc. President and CEO John Walter Hanna Jr., who is also a director, reported open-market sales of the company’s common stock. On January 21, 2026, he sold 200 shares at $21.00 per share, and on January 22, 2026, he sold 19,280 shares at a weighted average price of $21.163 per share. These transactions were coded as open market sales and were made under a Rule 10b5-1 trading plan adopted on December 13, 2024. Following the later transaction, he beneficially owned 597,405 shares of CareDx common stock directly.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported a sale of company stock. On January 15, 2026, he sold 10,156 shares of CareDx common stock in an open-market transaction coded as a sale. The shares were sold at a weighted average price of $21.052 per share, with individual trade prices ranging from $21.00 to $21.18.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on December 13, 2024, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, he beneficially owned 616,885 shares of CareDx common stock directly.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
